Skip to main content
. 2024 Aug 30;34(5):417–430. doi: 10.25259/ijn_319_23

Figure 1:

Figure 1:

Pathogenesis of IgAN and emerging therapies. Ang II: angiotensin II; APRIL: a proliferation-inducing ligand; AT1: angiotensin II subtype 1; BAFF: B-cell activating factor; ECM: extracellular matrix; eGFR: estimated glomerular filtration rate; ET-1: endothelin 1; ETA: endothelin A; GALT: gut-associated lymphoid tissue; GBM: glomerular basement membrane; Gd-IgA1-IC: galactose-deficient-IgA1 immune complex; IgA: immunoglobulin A; IgG: immunoglobulin G; IL-6: interleukin 6; NALT: nasopharynx-associated lymphoid tissue; TLR-9: toll-like receptor 9.